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Abstract 
Background 
Fever and neutropenia (FN) often complicate anticancer treatment and can be caused by 
potentially fatal infections. Knowledge of pathogen distribution is paramount for optimal 
patient management. 
Methods 
Microbiologically defined infections (MDI) in pediatric cancer patients presenting with FN 
by nonmyeloablative chemotherapy enrolled in a prospective multi-center study were 
analyzed. Effectiveness of empiric antibiotic therapy in FN episodes with bacteremia was 
assessed taking into consideration recently published treatment guidelines for pediatric 
patients with FN. 
Results 
MDI were identified in a minority (22%) of pediatric cancer patients with FN. In patients 
with, compared to without MDI, fever (median, 5 [IQR 3-8] vs. 2 [IQR1-3] days, p < 0.001) 
and hospitalization (10 [6-14] vs. 5 [3-8] days, p < 0.001) lasted longer, transfer to the 
intensive care unit was more likely (13 of 95 [14%] vs. 7 of 346 [2.0%], p < 0.001), and 
antibiotics were given longer (10 [7-14] vs. 5 [4-7], p < 0.001). Empiric antibiotic therapy in 
FN episodes with bacteremia was highly effective if not only intrinsic and reported 
antimicrobial susceptibilities were considered but the purposeful omission of coverage for 
coagulase negative staphylococci and enterococci was also taken into account (81% [95%CI 
68 - 90] vs. 96.6% [95%CI 87 - 99.4], p = 0.004) 
Conclusions 
MDI were identified in a minority of FN episodes but they significantly affected management 
and the clinical course of pediatric cancer patients. Compliance with published guidelines 
was associated with effectiveness of empiric antibiotic therapy in FN episodes with 
bacteremia. 
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Introduction 
Fever and neutropenia (FN) frequently complicate anticancer treatment and can be caused by 
potentially fatal infections 1. Successful management of FN is based on empiric antimicrobial 
treatment 2. Knowledge of expected pathogens, local antimicrobial susceptibility patterns, 
and the clinical course of FN episodes is important to optimize empiric treatment. Shifts in 
the spectrum of bacterial pathogens causing infections in patients with cancer and the 
emergence of resistant pathogens fuel the need for a constant surveillance of local conditions.  
The multicenter prospective Swiss Pediatric Oncology Group (SPOG) 2003 FN study was set 
up to develop prediction scores for adverse events 3 and bacteremia 4, and to do a randomized 
controlled trial of outpatient oral versus inpatient intravenous antibiotics in selected low risk 
episodes of FN 5. We describe here FN episodes with microbiologically defined infections 
(MDI), their management and clinical course, and the pathogens isolated in episodes with 
MDI in the SPOG 2003 FN study. 
Patients and Methods 
Study Design 
Details of the study design of the prospective multicenter SPOG 2003 FN study have been 
previously published 3,5. In brief, patients with cancer aged 1 to 18 years presenting with FN 
after nonmyeloablative chemotherapy were recruited by pediatric oncology centers in 
Switzerland and Germany between January 2004 and December 2007. Local and national 
ethics committees had approved the study. 
Patients and Management of FN 
In- and outpatients with cancer 1 to 18 years old were included in the study if they had fever, 
defined either as axillary temperature ≥ 38.5°C once, or ≥ 38.0°C for ≥ 2 hours 6, and 
neutropenia, defined as an absolute neutrophil count ≤ 0.5 G/L 6. At presentation with FN, all 
patients underwent a physical examination and blood was sampled for blood cultures and 
AC
CE
PT
ED
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
 5 
differential blood count. Empiric intravenous broad-spectrum antimicrobial therapy covering 
for Gram-positive (except methicillin-resistant Staphylococcus aureus (MRSA), coagulase-
negative staphylococci (CoNS), and Enterococcus species), and Gram-negative bacteria was 
started. The treating physician decided on further diagnostic procedures and supportive 
measures. Patients were observed as inpatients and reassessed within 8 to 24 hours after 
admission. If pre-specified restrictive low-risk criteria were fulfilled, they were offered to 
participate in the randomized controlled trial mentioned above (NCT00107081) 5. However, 
in the vast majority of episodes patients stayed hospitalized and were offered all standard 
diagnostic and therapeutic measures. This included escalation of antimicrobial treatment in 
patients with persistent fever to cover for CoNS, MRSA, enterococci, resistant Gram-
negative bacteria, and eventually fungal infections. 
Participating Centers 
Eight pediatric oncology centers from Switzerland (centers A to E) and Germany (centers F 
to H) participated in the SPOG 2003 FN study. Centers A, B, and C were located in the 
German-speaking, and centers D and E in the French-speaking part of Switzerland. All 
centers reported numbers and etiology of MDI, and results of antimicrobial susceptibility 
testing of bacterial pathogens isolated in blood cultures. Center A additionally reported time 
to positivity of pathogens isolated in blood cultures, and was the only center to implement a 
low-threshold testing strategy for viral respiratory infections. There were no differences in 
antibiotic prophylaxis regimens between centers. Only standard pneumocystis jirovecii 
prophylaxis was used in this study. 
Microbiologically Defined Infections 
Details on MDI definitions have been published 3,4. Essentially, initial aerobic and anaerobic 
blood cultures were taken at presentation with FN before starting antimicrobial therapy in all 
patients. Further blood cultures were taken daily if fever persisted or the patient experienced 
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shaking chills. Blood cultures were drawn from existing central venous catheters, if present, 
or a peripheral vein. Peripheral and central blood cultures were not performed in parallel. 
Bacteremia was defined as at least 1 positive blood culture, irrespective of the pathogen 
detected, using a qualitative automated culture system (BacT/ALERT, bioMérieux, Geneva, 
Switzerland; or BACTEC, Becton Dickinson, Basel, Switzerland) 4. For the analysis of time 
to positivity in center A, the time from loading of the blood culture vial into the incubator 
until detection of growth of microorganisms was considered. All pathogens identified in 
blood cultures were analyzed separately, provided they differed in species, morphology, 
antimicrobial susceptibility testing, or time point of sampling. 
Bacterial infections other than bacteremia were defined by a pathogen isolated from a 
normally sterile body fluid or compartment 3. 
Viral infections were defined by the detection of a viral antigen 7, or product of polymerase 
chain reaction by a validated microbiologic method. 
For this analysis, invasive fungal infections were defined according to the revised definitions 
of invasive fungal disease from the European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy 
and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group 8. 
 
Effectiveness of Empiric Antibiotic Treatment in FN Episodes with Bacteremia 
Effectiveness of empiric antibiotic therapy was assessed in three different ways. In vitro 
effectiveness was assessed based on reported and intrinsic antimicrobial susceptibilities to the 
antibiotics given on the day of sampling of the first positive blood culture. Effectiveness due 
to compliance with pediatric FN guidelines was defined by in vitro effectiveness restricted to 
pathogens to be covered by empiric antibiotic therapy according to current treatment 
recommendations for pediatric FN 9,10. Therefore, effectiveness due to compliance with 
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pediatric FN guidelines would be present even if a pathogen not covered by empiric 
antibiotic therapy (e.g., CoNS, or enterococci) was diagnosed from blood cultures sampled in 
the first 48 hours. 
Finally, microbiologic effectiveness was defined by the growth of bacterial pathogens in any 
blood culture after the initiation of empiric antibiotic therapy. 
 
Comparison of Bacteremia Causing Pathogens to the Swiss Centre for Antibiotic Resistance 
Database 
The Swiss Centre for Antibiotic Resistance (ANRESIS) 11,12 is an ongoing laboratory-based, 
representative surveillance system collecting antibiotic resistance data of actually 20 Swiss 
microbiology laboratories. For this analysis the distribution and antibiotic resistance of 
blood-borne pathogens detected in centers A, B, and C were compared to the corresponding 
population in the ANRESIS database. Data of centers D and E, located in the French-
speaking part of Switzerland, were excluded from this analysis due to the very low numbers 
of FN episodes with bacteremia reported (1 and 4 episodes, respectively). The ANRESIS 
population was defined as all positive blood cultures in children aged 2 - 15 years isolated 
during the years 2004 - 2007 in one of the Swiss German university children's hospitals 
participating also in the SPOG 2003 FN study. MDI with the same organism and the same 
resistance profile in the same patient were counted as different infections if the time interval 
between the two respective blood cultures exceeded 7 days. For this comparison, CoNS were 
judged as contaminants and excluded from analysis if isolated once within 7 days (ANRESIS 
population), or if clinically judged as non-significant, i.e. not treated or treated less than 5 
days with a glycopeptide antibiotic (SPOG 2003 FN study). 
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Statistics 
Proportions and their exact 95% Blyth-Still-Casella confidence intervals (95%CI) were 
calculated. Nonparametric exact two-sided tests were used throughout. Specifically, the 
Fisher's test, Fisher-Freeman-Halton test, Mann-Whitney U-test, Kruskall-Wallis test with 
Dunn's multiple comparison tests, and exact odds ratios (OR) of binomial proportions were 
calculated where applicable. For all statistical analyses, a two-sided p-value of 0.05 was 
considered significant. Statistical analyses were performed with GraphPad Prism 6.0 
(GraphPad Software, La Jolla CA, USA) and StatXact 10 (Cytel Inc., Cambridge MA, USA). 
 
Results 
Patients and Episodes of FN 
Eight German and Swiss pediatric oncology centers reported a total of 472 episodes of FN. 
Eligibility criteria were not fulfilled in 25 (5.3%) episodes, and follow-up was missing in 4 
(0.8%). Additionally 2 (0.4%) duplicate episodes were excluded. The remaining 441 (93.4%) 
FN episodes were analyzed here. Centers A, B, and C reported 171 (39%), 153 (35%), and 9 
(2%) FN episodes, respectively, while centers D to H reported the remaining 108 (24%) FN 
episodes. They occurred in 209 patients (median, 2 episodes per patient, interquartile range 
[IQR], 1-3), with a median age of 7.0 years (IQR 3.9 - 11.7) at the first FN episode. Further 
details have been published 3,4,13. 
An MDI was identified in 95 (22%; 95%CI 18-26) of these 441 FN episodes, bacteremia in 
67 (15%; 95%CI 12-19), a focal bacterial infection in 8 (1.8%; 95%CI 0.8-3.5), a viral 
infection in 29 (6.6%; 95%CI 4.5-9.2), and a fungal infection in 5 (1.1%; 95%CI 0.4-2.6). In 
12 (2.7%; 95%CI 1.5-4.6) of these 441 FN episodes more than one MDI was identified. 
Clinical Course of FN Episodes 
In FN episodes with versus without MDI fever persisted for a longer time (median, 5 [IQR 3-
8] vs. 2 [IQR 1-3] days, p < 0.001), patients were hospitalized longer (median, 10 [IQR 6-14] 
vs. 5 [IQR 3-8] days, p < 0.001), and transferred more often to the intensive care unit (ICU) 
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(13 of 95 [14%] vs. 7 of 346 [2.0%], OR 7.7, 95% CI 2.7 - 23.3, p < 0.001). Additionally, 
antimicrobial treatment in FN episodes with versus without MDI was more intensive as 
exemplified by a longer duration of intravenous antibiotic administration (median, 10 [IQR 7-
14] vs. 5 [IQR 4-7] days, p < 0.001), higher proportion of empiric antibiotic therapy 
escalation (67 of 95 [71%] vs. 106 of 346 [31%], OR 5.4, 95% CI 3.2 - 9.2, p < 0.001), and a 
higher proportion of empiric antifungal treatment (30 of 95 [32%] vs. 37 of 346 [11%], OR 
3.9, 95% CI 2.1 - 6.9, p < 0.001). Table 1 shows clinical and management related 
characteristics for the different categories of MDI compared to FN episodes without MDI. 
 
FN Episodes with Bacteremia 
In 67 FN episodes with bacteremia, a total of 83 pathogens were identified; 54 (65%) Gram-
positive and 29 (35%) Gram-negative bacteria (Table 2). There were no significant 
differences in fever duration, hospitalization length, proportion transferred to the ICU, 
duration of intravenous antibiotic treatment, escalation of antibiotic therapy, and duration of 
escalated antibiotic therapy between Gram-positive and Gram-negative bacteria (details not 
shown). Antimicrobial susceptibility testing was available for 68 (82%) of 83 blood culture 
isolates, but the important heterogeneity of susceptibility results available precluded 
meaningful comparisons. MRSA, vancomycin-resistant enterococci, or extended-spectrum 
beta-lactamase producing Gram-negative bacteria were not reported. 
 
Effectiveness of Empiric Antibiotic Therapy in FN Episodes with Bacteremia 
Table 3 specifies in vitro effectiveness versus effectiveness due to compliance with pediatric 
FN guidelines versus microbiologic effectiveness of empiric antibiotic therapy in the 67 FN 
episodes with bacteremia. In the 58 (87%) episodes with susceptibility results available, the 
effectiveness due to compliance with pediatric FN guidelines (56 of 58 episodes; 96.6% 
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[95%CI 87 - 99.4]) was significantly higher than the in vitro effectiveness (47 of 58 episodes; 
81% [95%CI 68 - 90], p = 0.004) and the microbiologic effectiveness (45 of 58 episodes; 
78% [95%CI 64 - 87], p = 0.003). CoNS bacteremia was the major reason for both in vitro (8 
of 11 [73%]) and microbiologic (11 of 14 [79%]) non-effectiveness. Applying only 
microbiologic effectiveness criteria, the initial empiric therapy failed in 10 (15%) of 67 FN 
episodes, while the escalated empiric therapy failed in 4 (7.7%) of 52 FN episodes. In one FN 
episode with clinical signs of a central venous catheter infection and empiric glycopeptide 
monotherapy, new Escherichia coli bacteremia was detected on day 3 of hospitalization. In 
both the in vitro and the microbiologic effectiveness scenarios, there were no significant 
differences in fever duration, hospitalization length, and proportion transferred to the ICU 
between FN episodes with bacteremia treated with effective versus ineffective initial empiric 
antibiotic therapy (details not shown).  
Of note, antibiotic therapy was escalated in 106 (31%) of 346 FN episodes without MDI. 
 
Time to positivity in FN Episodes with Bacteremia 
In center A, time to positivity was known in 33 (89%) of 37 blood cultures (31 of 34 FN 
episodes). In 27 (82%) of these 33 blood cultures a pathogen grew within 24 hours. All blood 
cultures with a time to positivity > 18 hours grew CoNS in monoculture (Figure 1). 
Correspondingly, for blood cultures with monocultural growth of CoNS time to positivity 
(19.8 hours [IQR 12.2 - 39]) was significantly longer than for blood cultures growing other 
Gram-positive bacteria (8.7 hours [IQR 4.1 - 11.5], p = 0.021) and blood cultures growing 
Gram-negative bacteria (4.2 hours [IQR 2.2 - 4.9], p = 0.001). Compared to blood cultures 
with polymicrobial growth only a trend was noted (7.9 hours [IQR 3.5 - 8.7], p = 0.051). 
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Comparison of Bacteremia Causing Pathogens to the Swiss Centre for Antibiotic  
Resistance Database 
The distribution of pathogens in 58 (87%) of 67 FN episodes with bacteremia observed in 
333 (76% of 441) FN episodes reported from centers A, B, and C was significantly different 
from the distribution of pathogens causing bacteremia in the general pediatric population of 
the German-speaking part of Switzerland (p < 0.001) (Table 4). 
CoNS (21% vs. 9.8%, p = 0.023) and viridans group streptococci (VGS) (29% vs. 9.3%, p < 
0.001) were detected more frequently in pediatric cancer patients with FN. In contrast, 
Streptococcus pneumoniae (0% vs. 24%, p < 0.001) was detected more frequently in the 
general pediatric population. 
Antimicrobial resistance did not differ significantly (details not shown). 
Other MDI 
 
A focal bacterial infection was microbiologically proven in 8 (1.8%) of 441 FN episodes(2 
urinary tract infections, 3 soft tissue infections, and 3 pneumonias). A viral infection was 
microbiologically proven in 29 (6.6%) of 441 FN episodes (in 25 FN episodes by antigen 
detection and in 4 FN episodes by polymerase chain reaction). In center A, the single center 
with a low-threshold viral testing strategy, the proportion was 13% (23 of 171 FN episodes, 
95%CI 9 - 19%). In 16 FN episodes an upper respiratory tract infection was diagnosed (1 
adenovirus, later diagnosed with fatal systemic adenovirus infection 14, 5 picornaviruses, 5 
influenza A viruses, 1 influenza B virus, 1 parainfluenza virus, 2 respiratory syncytial 
viruses, 1 human metapneumovirus), in 6 FN episodes herpes simplex virus stomatitis was 
diagnosed, in 3 FN episodes a systemic viral infection was diagnosed (1 adenovirus, initially 
presented as respiratory tract infection14, 1 herpes simplex virus, 1 cytomegalovirus), in 4 
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episodes a viral gastroenteritis was diagnosed (3 adenoviruses, 1 rotavirus), and in 1 FN 
episode herpes simplex virus encephalitis was diagnosed. 
An invasive fungal infection was diagnosed in 5 FN episodes, in two FN episodes the fungal 
infection was histologically proven and in three probable (Table 5). All invasive fungal 
infections were reported by center A, with a proportion of 2.9% (5 of 171, 95%CI 1.1 to 
6.4%). 
 
Discussion 
The aim of this study was to describe all MDI detected in the prospective multicenter SPOG 
FN 2003 study. In the majority of FN episodes (78%), no MDI was detected. Also, lack of 
MDI detection was associated with shorter duration of fever and hospitalization, less need of 
intensive care, and less intensive antimicrobial therapy compared to FN episodes with MDI. 
We detected MDI in around every fourth FN episode. Other studies of FN in pediatric cancer 
patients have reported comparable frequencies of MDI 15,16. Nevertheless, the perception that 
infections can be documented only in a minority of pediatric cancer patients with FN has 
been challenged by studies relying on systematic identification of viral infections by 
molecular methods 17-19. In two recent studies MDI were detected in 67% and 60% of FN 
episodes, with a respiratory virus infections being detected by molecular methods in 57% and 
46% of FN episodes respectively 17,18. This difference in the frequency of MDI is best 
explained by different diagnostic policies and procedures used for the detection of respiratory 
viral infections. In our study, even in the center with the most comprehensive strategy for 
respiratory viral diagnostics viral infections were only documented in 13% of all FN 
episodes. 
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The detection of any MDI versus no MDI was clearly associated with a more severe clinical 
course. The clinical course of FN episodes with bacteremia, however, did not relevantly 
differ from FN episodes with viral infection, except for a significantly longer administration 
and escalation of intravenous antibiotic therapy. The group with focal bacterial infections, 
fungal infections and mixed infections showed a more severe clinical course but the 
heterogeneity of this group prevented further conclusions. Nevertheless, a more severe 
clinical course of mixed viral and bacterial infections in FN has been reported before 17,18,20. 
Bacteremia was the most frequent and most reliably detected MDI in this study. Similar to 
other studies of FN in pediatric cancer patients, Gram-positive pathogens, mainly CoNS and 
VGS, constituted the majority of isolated pathogens 15,16,21. E. coli was the most frequent 
Gram-negative pathogen causing bacteremia. As expected the frequency of CoNS and VGS 
bacteremia differed significantly in patients with cancer and FN compared to the general 
pediatric population. Surprisingly, bacteremia caused by S. pneumoniae was not identified in 
our study population. Although, this contrasts with the general notion of cancer as a risk 
factor for invasive pneumococcal disease 22-24, it is strongly in line with other studies of 
pediatric cancer patients with FN 15,16,25. In other patient populations repetitive antibiotic 
therapy has been shown to reduce the carriage of S. pneumoniae, while the effect of 
cotrimoxazole prophylaxis was less clear 26. It is unlikely that vaccination against S. 
pneumoniae played a role in this study as the Swiss Federal Office of Public Health first 
issued a general recommendation for pneumococcal vaccination of children below 5 years of 
age only in 2006 and pediatric cancer patients were not specifically vaccinated against S. 
pneumoniae before chemotherapy start in this study. 
In a subset of FN episodes with bacteremia, a short time to positivity for both Gram-positive, 
with the exception of CoNS, and Gram-negative pathogens was observed. Comparable results 
have been reported and may favor an initial observation period of 24 hours for the evaluation 
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of chemotherapy induced FN in pediatric cancer patients 15. It should be noted, however, that 
in the SPOG 2003 FN study bacteremia was first detected in a subsequent blood culture in 11 
(2.5%) of 441 FN episodes (16% of 67 FN episodes with bacteremia) 4. A negative initial 
blood culture 24 hours after patient admission rendered a virulent Gram-negative or Gram-
positive bacteremia unlikely but did not exclude bacteremia as such. 
The effectiveness of empiric antibiotic therapy due to compliance with pediatric FN 
guidelines was high in this study. Nevertheless, in one FN episode Gram-negative bacteremia 
was detected on the third day of hospitalization only. In this patient, glycopeptide 
monotherapy had been started because of clinical signs of catheter infection, clearly not 
fulfilling the predefined requirements on initial empiric antibiotic therapy in pediatric cancer 
patients with FN. While CoNS bacteremia was proven in the blood culture sampled at 
presentation and on the catheter tip removed on the third day of hospitalization, E. coli 
bacteremia was identified in a blood culture sampled on the third day. This underlines once 
more the need of empiric coverage of Gram-negative pathogens by the initial antibiotic 
therapy of FN. 
CoNS bacteremia was the main reason for failure of empiric antibiotic therapy in this study. 
Empiric addition of glycopeptides to the first line empiric therapy has been evaluated in adult 
patients with cancer, but was not found to be superior to standard regimens in a meta-analysis 
27
. Escalation of antibiotic therapy to include coverage for CoNS is recommended in pediatric 
cancer patients if fever persists for more than 24 to 72 hours and they become clinically 
unstable 9,10. 
In this study, antibiotic therapy was escalated in almost one third of FN episodes without 
MDI. Unfortunately, it was not possible to reliably determine in how many of these episodes 
no deterioration of clinical condition, and thereby overtreatment, occurred. 
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This study has several limitations. First, this was an ad hoc analysis for which the SPOG 
2003 FN study was not designed for. Specifically, besides sampling of blood cultures all 
other microbiological investigations, diagnostic modalities, and clinical care practices were at 
the discretion of the treating physician. The low number of focal bacterial infections and viral 
infections identified in this study likely underestimates the actual burden of these MDI. 
Second, not all centers in this prospective multicenter study recruited patients consecutively 
and over the complete study duration. This may additionally favor underestimation of the 
burden of MDI, especially invasive fungal infections. Third, some analyses presented, e.g. 
time to positivity, could only be performed in subgroups of the study population due to 
different laboratory data collection practices. 
 
In this study MDI were identified in only a minority of FN episodes but they significantly 
affected management and the clinical course of patients. Compliance with recently published 
guidelines 9,10 was associated with effectiveness of empiric antibiotic therapy in FN episodes 
with bacteremia. 
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Figure Legend 
Figure 1: Distribution of time to positivity of 33 blood cultures processed in center A 
according to microbiologic etiology 
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Differences of clinical and management characteristics in 441 FN episodes according to the microbiologically defined 
infection  
 
 
 
Bacteremia 
only (n=55) 
Viral infection 
only (n=22) 
Focal bacterial, 
fungal, and mixed 
infections (n=18) 
No microbiologically 
defined infection 
(n=346) 
p-value 
Duration of fever (days) 4 (2 to 6)* 4.5 (2 to 7)* 9 (3 to 16.8)* 2 (1 to 3) < 0.001# 
Hospitalization length (days) 10 (8 to 13)* 7.5 (5 to 10)* 23.5 (6.8 to 30)* 5 (3 to 8) 
< 0.001# 
 
Episodes with transfer to ICU 
2 of 55 
(3.6%)§ 
2 of 22 
(9.1%)§ 
9 of 18 (50%)* 7 of 346 (2.0%) < 0.001†  
Duration of intravenous antibiotic 
therapy (days) 
11 (9 to 
14)*¶  
6.5 (4.8 to 
10.3) 
16 (9.8 to 23.8)*¶  5 (4 to 7) < 0.001# 
Episodes with escalation of antibiotic 
therapy 
42 of 55 
(76%)¶* 
10 of 22 
(46%)§ 
15 of 18 (83%)* 106 of 346 (31%) < 0.001†  AC
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Duration of escalated antibiotic 
therapy (days) (n=173) 
10 (7 to 12)* 
(n=42) 
6.5 (4.8 to 
16) (n=10) 
13 (10 to 21)* 
(n=15) 
6 (4 to 8.3) (n=106) < 0.001# 
Episodes with escalation of antibiotic 
therapy of those with fever > 48h 
(n=260) 
36 of 46 
(78%)* 
10 of 18 
(56%) 
14 of 17 (82%)* 87 of 179 (49%) < 0.001†  
Episodes with antifungal therapy 
15 of 55 
(27%)* 
7 of 22 
(32%)* 
8 of 18 (44%)* 37 of 346 (11%) < 0.001†  
Episodes with antifungal therapy of 
those with fever > 96h (n=105) 
13 of 21 
(62%) 
7 of 11 (64%) 7 of 11 (64%) 25 of 62 (40%) 0.17†  
C-reactive protein at presentation 
(mg/L) (n=428) 
46.5 (30.8 
to 78.8) 
(n=52) 
26 (10.5 to 
97) (n=21) 
41.5 (25 to 105.3) 
(n=18) 
37 (15 to 81.5) (n=337) 0.2# 
 
 
Data are presented as median (interquartile range), unless otherwise indicated. 
* Significantly different to the group with no microbiologically defined infection (Dunn's multiple comparison test) AC
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¶ Significantly different to the group with viral infection solely (Dunn's multiple comparison test) 
§ Significantly different to the group with focal bacterial, fungal, and mixed infections (Fisher's exact test) 
# Kruskall-Wallis test, significant differences between groups were estimated with Dunn's multiple comparison test 
† Fisher-Freeman-Halton test, significant differences between groups were estimated with Fisher's exact test 
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Positive blood culture results defining bacteremia in 441 FN episodes 
 
  Time of blood culture sampling 
 All < 48 hours > 48 hours 
Bacteria cultured 83 68 15 
 Gram-positive bacteria 54 40 14 
Staphylococcus aureus 4 4  
Coagulase negative 
staphylococci 
27 14 13 
Viridans group streptococci 20 20  
Enterococcus species 2 1 1 
Rothia mucilaginosa 1 1  
Gram-negative bacteria 29 28 1 
Escherichia coli 15 14 1 
Pseudomonas aeruginosa 6 6  
Klebsiella pneumoniae 3 3  AC
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Neisseria species (not 
meningitidis) 
2 2  
Capnocytophaga species 2 2  
Enterobacter cloacae 1 1  
FN episodes with bacteremia 67 60 7 
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Effectiveness of empirical antibiotic therapy in 67 FN episodes with bacteremia 
 
 
 
Diagnostic blood 
culture sampled <= 
48 hours 
Diagnostic blood culture 
sampled > 48 hours 
All FN episodes 
In vitro (n=58)*  44 of 54† 3 of 4§ 47 of 58 (81%) 
Due to compliance with pediatric FN 
guidelines (n=58)* 
 53 of 54¶ 3 of 4§ 56 of 58 (96.6%) 
Microbiologic (n=67)  53 of 63# 0 of 4‡ 53 of 67 (79.1%) 
 
 
* In 9 FN episodes antimicrobial susceptibility testing was not available  
 
† Not effective in 8 CoNS, 1 Enterococcus faecalis, 1 VGS resistant to penicillin and ceftriaxone (further testing not available) 
§ Not effective in 1 Enterococcus avium 
¶ Not effective in 1 VGS resistant to penicillin and ceftriaxone (further testing not available) AC
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# Not effective in 7 CoNS, 1 Staphylococcus aureus, 1 VGS, and 1 FN episode with persistent CoNS bacteremia and new 
Escherichia coli bacteremia on day 3 of hospitalization 
‡ Not effective in 3 CoNS, 1 Enterococcus avium 
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Comparison of the distribution of pathogens causing bacteremia in the German-speaking part of Switzerland between 
centers A, B, and C of the SPOG 2003 FN study and the general pediatric population (ANRESIS 2004 - 2007) 
 
 
Pathogen SPOG 2003 
(n=58) 
ANRESIS 2004-
2007 (n=378) 
p-value* 
Staphylococcus aureus 4 (6.9%) 64 (17%) 0.052 
Coagulase negative staphylococci 12 (21%) 37 (9.8%) 0.023 
Streptococcus pneumoniae 0 (0%) 89 (24%) < 0.001 
Viridans group streptococci 17 (29%) 35 (9.3%) < 0.001 
Streptococcus pyogenes 0 (0%) 6 (1.6%) 0.61 
Enterococcus species 1 (1.7%) 11 (2.9%) 1 
Enterobacteriaceae † 15 (26%) 90 (24%) 0.74 
Pseudomonas aeruginosa 5 (8.6%) 22 (5.8%) 0.56 
Neisseria species 1 (1.7%) 1 (0.3%) 0.24 
Haemophilus influenzae 0 (0%) 6 (1.6%) 0.61 AC
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Moraxella catarrhalis 0 (0%) 1 (0.3%) 1 
Others 3 (5.2%) 16 (4.2%) 0.72 
Total 58 378  
 
* Fisher's exact test, not corrected for multiple testing. Overall comparison using Fisher-Freeman-Halton test, p < 0.001 
† Enterobacter cloacae (1 in SPOG 2003 vs. 8 in ANRESIS), Escherichia coli (11 vs. 40), Klebsiella species (3 vs. 16), Morganella 
morganii (0 vs. 2), Proteus species (0 vs. 4), Salmonella species (0 vs. 15), Citrobacter species (0 vs. 5) 
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Invasive fungal infections diagnosed in 5 of 441 FN episodes 
 
Type of 
fungus 
 
Diagnostic test Sampling 
location 
Focal 
disease 
manifestation 
Classification 
of disease 8 
Day of diagnosis 
(from presentation 
with FN) 
Oncologic 
diagnosis 
Outcome * 
Aspergillus 
fumigatus 
galactomannan 
assay 
bronchial 
lavage 
radiological 
lung 
consolidation 
probable 7 ALL relapse survived 
Mucor 
species 
histology biopsy of 
nasal 
septum 
periorbital 
cellulitis 
proven 11 PreB ALL died  from 
rhino cerebral 
mucormycosi
s 
Aspergillus 
fumigatus 
galactomannan 
assay, PCR 
bronchial 
lavage 
radiological 
lung 
consolidation 
probable 13 ALL relapse survived 
Absidia culture biopsy of perinasal proven 4 AML survived AC
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corymbifera nose and 
soft 
tissue of 
the face 
Cellulitis 
Aspergillus 
fumigatus 
galactomannan 
assay 
blood radiological 
lung 
consolidation 
probable 8 AML survived 
 
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; PCR, polymerase chain reaction 
* The outcome of FN episodes was monitored until 7 days after completion of antimicrobial therapy and recovery of neutropenia. 
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